Cumberland Pharmaceuticals Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CPIX Nasdaq 2830 www.cumberlandpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference - Jun 23rd, 2025 7:05 am
Investors in Cumberland Pharmaceuticals (NASDAQ:CPIX) have seen splendid returns of 235% over the past year - Jun 2nd, 2025 6:02 am
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS - May 27th, 2025 2:05 pm
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH - May 13th, 2025 2:05 pm
Cumberland Pharmaceuticals Inc (CPIX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - May 7th, 2025 1:20 am
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 - May 6th, 2025 2:05 pm
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE - Apr 29th, 2025 2:05 pm
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference - Mar 19th, 2025 2:05 pm
Cumberland Pharmaceuticals Full Year 2024 Earnings: US$0.46 loss per share (vs US$0.44 loss in FY 2023) - Mar 13th, 2025 4:55 am
Cumberland Pharmaceuticals Inc (CPIX) Q4 2024 Earnings Call Highlights: Revenue Growth and ... - Mar 5th, 2025 12:09 am
Cumberland: Q4 Earnings Snapshot - Mar 4th, 2025 2:50 pm
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth - Mar 4th, 2025 2:05 pm
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS - Feb 25th, 2025 2:05 pm
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA - Feb 18th, 2025 5:30 am
Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD - Feb 5th, 2025 3:23 am
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease - Feb 4th, 2025 11:31 am
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease - Feb 4th, 2025 5:30 am
3 US Penny Stocks With Market Caps Over $30M - Jan 16th, 2025 1:06 pm
3 Promising Penny Stocks With Market Caps Under $2B In US - Dec 10th, 2024 5:09 pm
Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change - Dec 10th, 2024 11:39 am